PMID- 23880927
OWN - NLM
STAT- MEDLINE
DCOM- 20140401
LR  - 20211021
IS  - 1660-3397 (Electronic)
IS  - 1660-3397 (Linking)
VI  - 11
IP  - 7
DP  - 2013 Jul 4
TI  - pH-dependent solution structure and activity of a reduced form of the 
      host-defense peptide myticin C (Myt C) from the mussel Mytilus galloprovincialis.
PG  - 2328-46
LID - 10.3390/md11072328 [doi]
AB  - Myticin C (Myt C) is a highly variable host-defense peptide (HDP) associated to 
      the immune response in the mediterranean mussel (Mytilus galloprovincialis), 
      which has shown to be active across species due to its strong antiviral activity 
      against a fish rhabdovirus found in fish cells overexpressing this HDP. However, 
      the potential antimicrobial properties of any synthetic analogue of Myt C has not 
      yet been analysed. Thus, in this work we have synthesised the sequence of the 
      mature peptide of Myt C variant c and analysed the structure activity 
      relationships of its reduced (non-oxidized) form (red-MytCc). In contrast to 
      results previously reported for oxidized isoforms of mussel myticins, red-MytCc 
      was not active against bacteria at physiological pH and showed a moderate 
      antiviral activity against the viral haemorrhagic septicaemia (VHS) rhabdovirus. 
      However, its chemotactic properties remained active. Structure/function studies 
      in neutral and acid environments by means of infrared spectroscopy indicated that 
      the structure of red-MytCc is pH dependent, with acid media increasing its 
      alpha-helical content. Furthermore, red-MytCc was able to efficiently aggregate 
      artificial phospholipid membranes at low pH, as well as to inhibit the 
      Escherichia coli growth, suggesting that this activity is attributable to its 
      more structured form in an acidic environment. All together, these results 
      highlight the dynamic and environmentally sensitive behavior of red-Myt C in 
      solution, and provide important insights into Myt C structure/activity 
      relationships and the requirements to exert its antimicrobial/immunomodulatory 
      activities. On the other hand, the pH-dependent direct antimicrobial activity of 
      Myt C suggests that this HDP may be a suitable template for the development of 
      antimicrobial agents that would function selectively in specific pH environments, 
      which are sorely needed in this "antibiotic-resistance era".
FAU - Martinez-Lopez, Alicia
AU  - Martinez-Lopez A
AD  - Molecular and Cell Institute, University Miguel Hernandez (IBMC-UMH), Elche 
      03202, Spain. alicia.martinez@umh.es
FAU - Encinar, Jose Antonio
AU  - Encinar JA
FAU - Medina-Gali, Regla Maria
AU  - Medina-Gali RM
FAU - Balseiro, Pablo
AU  - Balseiro P
FAU - Garcia-Valtanen, Pablo
AU  - Garcia-Valtanen P
FAU - Figueras, Antonio
AU  - Figueras A
FAU - Novoa, Beatriz
AU  - Novoa B
FAU - Estepa, Amparo
AU  - Estepa A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130704
PL  - Switzerland
TA  - Mar Drugs
JT  - Marine drugs
JID - 101213729
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Antimicrobial Cationic Peptides)
RN  - 0 (Antiviral Agents)
RN  - 0 (Blood Proteins)
RN  - 0 (Peptides)
RN  - 0 (Protein Isoforms)
RN  - 0 (Solutions)
RN  - 0 (myticin)
RN  - 0 (polypeptide C)
SB  - IM
MH  - Animals
MH  - Anti-Infective Agents/chemistry/pharmacology
MH  - Antimicrobial Cationic Peptides/*chemistry/pharmacology
MH  - Antiviral Agents/chemistry/pharmacology
MH  - Bivalvia/*chemistry
MH  - Blood Proteins/*chemistry/pharmacology
MH  - Cells, Cultured
MH  - Escherichia coli/drug effects
MH  - Fishes
MH  - Hydrogen-Ion Concentration
MH  - Mytilus/*chemistry
MH  - Peptides/*chemistry/pharmacology
MH  - Protein Isoforms/*chemistry/pharmacology
MH  - Protein Structure, Secondary
MH  - Rhabdoviridae/drug effects
MH  - Solutions/*chemistry
MH  - Structure-Activity Relationship
PMC - PMC3736426
EDAT- 2013/07/25 06:00
MHDA- 2014/04/02 06:00
PMCR- 2013/07/01
CRDT- 2013/07/25 06:00
PHST- 2013/04/23 00:00 [received]
PHST- 2013/05/30 00:00 [revised]
PHST- 2013/06/07 00:00 [accepted]
PHST- 2013/07/25 06:00 [entrez]
PHST- 2013/07/25 06:00 [pubmed]
PHST- 2014/04/02 06:00 [medline]
PHST- 2013/07/01 00:00 [pmc-release]
AID - md11072328 [pii]
AID - marinedrugs-11-02328 [pii]
AID - 10.3390/md11072328 [doi]
PST - epublish
SO  - Mar Drugs. 2013 Jul 4;11(7):2328-46. doi: 10.3390/md11072328.